ATE431403T1 - Fvii oder fviia varianten - Google Patents

Fvii oder fviia varianten

Info

Publication number
ATE431403T1
ATE431403T1 AT04722232T AT04722232T ATE431403T1 AT E431403 T1 ATE431403 T1 AT E431403T1 AT 04722232 T AT04722232 T AT 04722232T AT 04722232 T AT04722232 T AT 04722232T AT E431403 T1 ATE431403 T1 AT E431403T1
Authority
AT
Austria
Prior art keywords
fvii
variants
fviia variants
rhfviia
hfviia
Prior art date
Application number
AT04722232T
Other languages
German (de)
English (en)
Inventor
Kim Andersen
Mads Roepke
Jesper Haaning
Steven Glazer
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Application granted granted Critical
Publication of ATE431403T1 publication Critical patent/ATE431403T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04722232T 2003-03-20 2004-03-22 Fvii oder fviia varianten ATE431403T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45654703P 2003-03-20 2003-03-20
US47970803P 2003-06-19 2003-06-19
PCT/DK2004/000193 WO2004083361A2 (en) 2003-03-20 2004-03-22 FVII OR FVIIa VARIANTS

Publications (1)

Publication Number Publication Date
ATE431403T1 true ATE431403T1 (de) 2009-05-15

Family

ID=33032721

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04722232T ATE431403T1 (de) 2003-03-20 2004-03-22 Fvii oder fviia varianten

Country Status (10)

Country Link
US (2) US7771996B2 (OSRAM)
EP (2) EP1608745B1 (OSRAM)
JP (2) JP4847856B2 (OSRAM)
AT (1) ATE431403T1 (OSRAM)
AU (2) AU2004221761B2 (OSRAM)
CA (1) CA2519873C (OSRAM)
DE (1) DE602004021099D1 (OSRAM)
DK (2) DK2085470T3 (OSRAM)
ES (2) ES2327044T3 (OSRAM)
WO (1) WO2004083361A2 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
JP2003521930A (ja) * 2000-02-11 2003-07-22 マキシゲン・エイピーエス 第ＶＩＩ因子または第ＶＩＩａ因子様分子
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
CN1665925A (zh) * 2002-04-30 2005-09-07 马克西根控股公司 凝血因子Ⅶ或Ⅶa多肽变体
AU2004221761B2 (en) 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
EP1644504B8 (en) 2003-06-19 2010-06-02 Bayer HealthCare LLC Factor vii or viia gla domain variants
DK1781782T3 (da) 2004-08-17 2010-08-23 Csl Behring Gmbh Modificerede vitamin K-afhængige polypeptider
EP1893230A2 (en) * 2005-04-26 2008-03-05 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
ES2553160T3 (es) 2005-06-17 2015-12-04 Novo Nordisk Health Care Ag Reducción y derivatización selectivas de proteínas Factor VII transformadas por ingeniería que comprenden al menos una cisteína no nativa
EP1904528B1 (en) 2005-07-13 2012-10-31 Novo Nordisk Health Care AG Host cell protein knock-out cells for production of therapeutic proteins
EP1924689B1 (en) 2005-09-01 2014-08-13 Novo Nordisk Health Care AG Hydrophobic interaction chromatography purification of factor vii polypeptides
US20090055942A1 (en) 2005-09-14 2009-02-26 Novo Nordisk Healthcare A/G Human Coagulation Factor VII Polypeptides
ES2399138T3 (es) * 2006-03-16 2013-03-26 Stellaris Pharmaceuticals Aps Tratamiento local con factor VII
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
AU2013204377B2 (en) * 2007-04-13 2015-07-16 Catalyst Biosciences, Inc. Modified factor vii polypeptides and uses thereof
UA101155C2 (ru) * 2007-04-13 2013-03-11 Каталист Байосайенс, Инк. Модифицированный полипептид фактора vii (fvii) и его применение
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
CA3185756A1 (en) 2012-12-24 2014-07-03 Coagulant Therapeutics Corporation Short-acting factor vii polypeptides
MX2020003351A (es) 2017-09-27 2020-10-12 Sigilon Therapeutics Inc Metodos, composiciones y elementos implantables que comprenden celulas activas.
IL277713B2 (en) 2018-04-04 2024-09-01 Sigilon Therapeutics Inc Implantable particles and related methods
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
CN120659872A (zh) 2022-10-11 2025-09-16 西吉隆医疗股份有限公司 用于治疗疾病的经工程化的细胞和可植入元件

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5258288A (en) 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
FI882746A7 (fi) 1987-06-12 1988-12-13 Hoechst Japan Hybridiproteiini C ja menetelmä sen valmistamiseksi.
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
ES2052368T3 (es) 1990-01-26 1994-07-01 Immuno Ag Factores sanguineos producidos por recombinacion y el proceso para la expresion de dichos factores, asi como recombinacion del virus de vaccina usados en dicho proceso.
JP3330932B2 (ja) 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 抗凝固剤タンパク質
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
EP0785273A1 (en) 1990-11-26 1997-07-23 Genetics Institute, Inc. Paired basic amino acid converting enzyme and DNA sequence encoding it
US5861374A (en) 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
HU218890B (hu) 1991-02-28 2000-12-28 Novo Nordisk A/S Véralvadást gátló módosított VII faktorok, ezeket kódoló polinukleotid molekulák, polinukleotid molekulával transzfektált emlős sejtek és a véralvadást gátló módosított VII faktorokat tartalmazó gyógyászati készítmények, valamint a készítmények ...
US5817788A (en) 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5504064A (en) 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
JPH0720127A (ja) 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
PT699075E (pt) 1993-05-21 2002-05-31 Novo Nordisk As Factor vii modificado para inibicao de restenose vascular e de deposicao de plaquetas
DE19531637A1 (de) 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US5837843A (en) 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
JP2001523949A (ja) 1996-11-08 2001-11-27 オクラホマ メディカル リサーチ ファウンデーション 改変したプロテインｃおよびその使用方法
BR9806793A (pt) * 1997-01-22 2000-05-16 Univ Texas Processos e composições de fator tissular para coagulação e tratamento de tumores.
DE69800640T2 (de) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
EP1017794A1 (en) 1997-02-06 2000-07-12 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
EP1005361B1 (en) 1997-07-18 2010-01-06 Novo Nordisk Health Care AG USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
JP4574007B2 (ja) 1998-04-28 2010-11-04 メルク・セローノ・ソシエテ・アノニム ポリオール−ｉｆｎ−ベータ複体
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
NZ511291A (en) 1998-10-30 2003-08-29 Novozymes As A method for selecting a protein variant that has reduced immunogenicity as compared with the parent or wild-type protein
AU774156B2 (en) 1998-10-30 2004-06-17 Novozymes A/S Glycosylated proteins having reduced allergenicity
WO2000028065A1 (en) 1998-11-06 2000-05-18 Novo Nordisk A/S Method for the production of fvii
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
JP2003521930A (ja) 2000-02-11 2003-07-22 マキシゲン・エイピーエス 第ＶＩＩ因子または第ＶＩＩａ因子様分子
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
ES2449224T3 (es) * 2000-05-03 2014-03-18 Novo Nordisk Health Care Ag Administración subcutánea del Factor de coagulación VII
DE60143292D1 (de) 2000-05-03 2010-12-02 Novo Nordisk Healthcare Ag Varianten des menschlichen Koagulationsfaktors VII
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
PL204888B1 (pl) * 2000-09-13 2010-02-26 Novo Nordisk Healthcare Ag Wariant polipeptydu czynnika VII, konstrukcja kwasu nukleinowego, rekombinowana komórka gospodarza, zwierzę transgeniczne, sposób wytwarzania wariantu polipeptydu czynnika VII, kompozycja farmaceutyczna i zastosowanie wariantu polipeptydu czynnika VII
BR0113854A (pt) 2000-09-13 2004-07-06 Novo Nordisk As Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal
EP1325113B1 (en) 2000-10-02 2010-04-21 Novo Nordisk Health Care AG Factor vii glycoforms
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
WO2002077218A1 (en) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
ES2376694T3 (es) 2001-09-27 2012-03-16 Novo Nordisk Health Care Ag Polipã‰ptidos del factor vii de coagulaciã“n humano.
AU2002336919A1 (en) 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
BR0215216A (pt) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
CN1665925A (zh) 2002-04-30 2005-09-07 马克西根控股公司 凝血因子Ⅶ或Ⅶa多肽变体
ATE505487T1 (de) 2002-09-30 2011-04-15 Bayer Healthcare Llc Fvii- oder fviia-varianten mit erhöhter koagulationswirkung
AU2004221761B2 (en) 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
EP1644504B8 (en) * 2003-06-19 2010-06-02 Bayer HealthCare LLC Factor vii or viia gla domain variants
WO2005023308A1 (en) * 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins

Also Published As

Publication number Publication date
ES2327044T3 (es) 2009-10-23
CA2519873A1 (en) 2004-09-30
JP2012095641A (ja) 2012-05-24
AU2004221761A1 (en) 2004-09-30
DE602004021099D1 (de) 2009-06-25
US20100330669A1 (en) 2010-12-30
WO2004083361A3 (en) 2004-11-04
EP1608745B1 (en) 2009-05-13
EP1608745A2 (en) 2005-12-28
US7771996B2 (en) 2010-08-10
WO2004083361A2 (en) 2004-09-30
ES2386010T3 (es) 2012-08-07
AU2010201201A1 (en) 2010-04-15
JP2006521098A (ja) 2006-09-21
DK1608745T3 (da) 2009-06-15
AU2004221761B2 (en) 2010-01-07
EP2085470B1 (en) 2012-05-16
CA2519873C (en) 2012-12-18
JP4847856B2 (ja) 2011-12-28
EP2085470A1 (en) 2009-08-05
DK2085470T3 (da) 2012-08-06
US20070054366A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
ATE431403T1 (de) Fvii oder fviia varianten
DK1263941T3 (da) Xylanasevarianter med ændret sensitivitet overfor xylanaseinhibitorer
DK1549677T3 (da) FVII- eller FVIIa-varianter med forøget koagulationsaktivitet
NO2017027I2 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
WO2007031559A3 (en) Human coagulation factor vii polypeptides
CY1111626T1 (el) ΠΑΡΑΛΛΑΓΕΣ ΠΟΛΥΠΕΠΤΙΔΙΩΝ ΠΑΡΑΓΟΝΤΑ VII ´H VIIa
TR199902751T2 (xx) Proteaz inhibit�rleri.
CY1110185T1 (el) Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19
GB0206711D0 (en) HIF Inhibitor
DE602007001467D1 (de) Therapeutische Zubereitung von hochreinem FVIIa und Verfahren zu dessen Gewinnung
EP1689766A4 (en) EXPRESSION OF PROTEASE INHIBITORS AND VARIANTS THEREOF IN FILAMENTOUS MUSHROOMS
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE60306934D1 (de) Verwendung von Nitrilenverbindungen als Arztneimittel
LT2004074A (en) Matricines metalproteinazes inhibuojanti kompozicija neoplazinems ligoms gydyti
WO2006114105A3 (en) Use of modified factor vii for treating bleeding
DK2284251T3 (da) Alkalisk protease med forøget specifik aktivitet over for casein
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
DE50206480D1 (de) Antimikrobiell wirkendes peptid
ATE289319T1 (de) Dipeptidische hemmstoffe für den gerinnungsfaktor xa
WO2004110469A3 (en) Formulations comprising factor viia and a factor vii related polypeptide
BRPI0409566A (pt) compostos de ácido fosfÈnico como inibidores de serina protease
ATE452002T1 (de) Trennscheibe
FR2896693B1 (fr) Composition comprenant plusieurs toxines botuliques
ATE337704T1 (de) Zusammensetzungen mit biostimulierender wirksamkeit
NO20031398D0 (no) Ovalpigg og bildekk med pigger

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties